172 related articles for article (PubMed ID: 36067528)
21. Acrodermatitis continua Hallopeau successfully treated by risankizumab.
Hugo J; Gkalpakioti P; Arenbergerova M; Arenberger P; Gkalpakiotis S
Int J Dermatol; 2021 Apr; 60(4):e144-e145. PubMed ID: 33368238
[No Abstract] [Full Text] [Related]
22. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis.
Mugheddu C; Atzori L; Lappi A; Pau M; Murgia S; Rongioletti F
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e420-e421. PubMed ID: 28319281
[No Abstract] [Full Text] [Related]
23. A drug safety evaluation of risankizumab for psoriasis.
Huang YW; Tsai TF
Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
[No Abstract] [Full Text] [Related]
24. Acrodermatitis continua of Hallopeau in an elderly patient successfully and rapidly treated with risankizumab: a case report.
Orsini D; Iacovelli P; Frascione P; Pacifico A
J Dermatolog Treat; 2023 Dec; 34(1):2229468. PubMed ID: 37381703
[No Abstract] [Full Text] [Related]
25. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
26. Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series.
Dawoud NM; El Badawy MB; Al Eid HS; Abdel Fattah MM
Indian J Dermatol Venereol Leprol; 2022; 88(2):235-240. PubMed ID: 35138060
[No Abstract] [Full Text] [Related]
27. Risankizumab for the treatment of moderate to severe psoriasis.
Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
[No Abstract] [Full Text] [Related]
28. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
31. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
Maçães CO; Lé AM; Torres T
J Dermatolog Treat; 2022 Nov; 33(7):2911-2918. PubMed ID: 35695278
[TBL] [Abstract][Full Text] [Related]
32. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
Li L; Wu Z; Wu M; Qiu X; Wu Y; Kuang Z; Wang L; Sun T; Liu Y; Yi S; Jing H; Zhou S; Chen B; Wu D; Wu W; Liu J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107008. PubMed ID: 33069927
[TBL] [Abstract][Full Text] [Related]
33. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
[TBL] [Abstract][Full Text] [Related]
34. Generalized Pustular Psoriasis Treated With Risankizumab.
Song EJ
Cutis; 2023 Feb; 111(2):96-98. PubMed ID: 37075177
[No Abstract] [Full Text] [Related]
35. Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient.
Megna M; Abategiovanni L; Annunziata A; Torta G; Peduto T; Fabbrocini G; Lauro W
Dermatol Ther; 2022 May; 35(5):e15382. PubMed ID: 35170168
[No Abstract] [Full Text] [Related]
36. Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab.
Huang D; Liu T; Li J; Lu Y; Ma H
Dermatol Ther; 2022 Dec; 35(12):e15878. PubMed ID: 36181408
[No Abstract] [Full Text] [Related]
37. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
38. Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.
Hou M; Xing H; Cai Y; Wang X; Xie Z; Zhang Q; Ma Y; Chen J
Eur J Dermatol; 2019 Jun; 29(3):302-314. PubMed ID: 31389789
[TBL] [Abstract][Full Text] [Related]
39. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
[TBL] [Abstract][Full Text] [Related]
40. Sequential use of infliximab and etanercept in generalized pustular psoriasis.
Weisenseel P; Prinz JC
Cutis; 2006 Sep; 78(3):197-9. PubMed ID: 17036664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
